AlphaYouBH
Insider selling
Benjamin Hohl sold $264K of Enliven Therapeutics, Inc. (ELVN) stock
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares of ELVN stock worth $264K, per an SEC Form 4 filed Jun 22, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Jun 17, 2026, 5 days before it was made public.
ELVN has moved +8.9% since the trade date, from $44.86 to $48.87 (Sep 21, 2026 close).
- Traded
- Jun 17, 2026
- Disclosed
- Jun 22, 2026
- Filing delay
- 5 days
- Price since
- +8.9%
- Role
- Chief Financial Officer
- Source
- SEC Form 4
More ELVN insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.